Singapore markets closed
Straits Times Index
3,331.70 +5.42 (+0.16%) S&P 500
5,462.60 -6.70 (-0.12%) Dow
38,979.56 -132.60 (-0.34%) Nasdaq
17,765.44 +47.78 (+0.27%) Bitcoin USD
61,735.85 -220.62 (-0.36%) CMC Crypto 200
1,282.72 -1.06 (-0.08%)
ITCI Dec 2024 110.000 put
OPR - OPR Delayed price. Currency in USD
Add to watchlist
As of 10:30AM EDT. Market open.
| Previous close | 45.30 |
| Open | 45.30 |
| Bid | 39.90 |
| Ask | 44.50 |
| Strike | 110.00 |
| Expiry date | 2024-12-20 |
| Day's range | 45.30 - 45.30 |
| Contract range | N/A |
| Volume | |
| Open interest | N/A |
ZacksIntra-Cellular's (ITCI) Caplyta Boosts Sales, Dependence a Woe
Intra-Cellular (ITCI) is witnessing strong Caplyta sales, driven by an increasing prescription rate. However, the company is heavily dependent on Caplyta sales for growth, which is a concern.
ZacksBiotech Stock Roundup: ITCI Up on Study Data, ZNTL, OVID Down on Updates & More News
Intra-Cellular Therapies (ITCI) and Zentalis Pharmaceuticals, Inc. (ZNTL) are in the spotlight following pipeline and regulatory updates, respectively.
ZacksIntra-Cellular (ITCI) Up as Second Depression Study Meets Goals
Intra-Cellular (ITCI) gains 10% after achieving key goals in the second late-stage study evaluating lumateperone 42 mg as an adjunctive therapy to antidepressants for the treatment of MDD.
© 2024 Yahoo. All rights reserved.